News from bioinvent A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 20, 2021, 05:47 ET BioInvent to host Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Jan 11, 2021, 02:28 ET BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces it has restructured a clinical development agreement with...


Dec 22, 2020, 23:42 ET BioInvent receives $3 million payment related to selection of antibodies under collaboration with Pfizer Inc.

BioInvent International AB (OMXS: BINV ), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...


Dec 21, 2020, 02:55 ET BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Dec 09, 2020, 03:09 ET Nomination Committee appointed for BioInvent International's Annual General Meeting 2021

The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent) Annual General Meeting in 2021 have now been appointed....


Dec 07, 2020, 02:42 ET Record date for reverse share split in BioInvent International determined

At the Extraordinary General Meeting of BioInvent International AB (publ) ("BioInvent") on 27 November 2020, a reverse share split was resolved upon, ...


Nov 27, 2020, 05:42 ET Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020

BioInvent International AB's (publ) ("BioInvent") (OMXS: BINV) Extraordinary General Meeting (the "EGM") today resolved to approve the Board of...


Nov 27, 2020, 04:08 ET BioInvent strengthens Investor Relations

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Nov 26, 2020, 02:50 ET BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10

Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of...


Nov 09, 2020, 08:15 ET BioInvent and Transgene present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Nov 09, 2020, 08:08 ET BioInvent presents new preclinical data on BI-1808, a first-in-class anti-TNFR2 antibody at the SITC 35th Anniversary Annual Meeting

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Nov 04, 2020, 11:58 ET BioInvent presents promising new clinical and preclinical data on anti-FcγRllB antibody, BI-1206, at the ASH Annual Meeting

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV), a biotech company focused on the discovery and development of novel and...


Oct 29, 2020, 03:15 ET BioInvent Interim Report January 1 - September 30, 2020

China licensing agreement further validates technology and strategy "The exclusive licensing agreement with CASI Pharmaceuticals for BI-1206 in China ...


Oct 27, 2020, 04:35 ET Notice to Extraordinary General Meeting in BioInvent International AB

The Board of Directors in BioInvent International AB ("BioInvent" or the "Company") has resolved: To issue shares and warrants to CASI...


Oct 27, 2020, 04:02 ET BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV), a biotechnology company focused on the discovery and development of...


Oct 26, 2020, 09:24 ET CTA approval of BioInvent's BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on novel and first-in-class immune-modulatory antibodies for cancer...


Oct 22, 2020, 01:07 ET BioInvent receives €2 million milestone from Daiichi Sankyo

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it will receive a €2 million milestone payment under its...


Oct 15, 2020, 03:06 ET BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Oct 15, 2020, 02:44 ET BioInvent to present data on BI-1808, an anti-TNFR2 antibody, at the SITC 35th Anniversary Annual Meeting

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


Aug 27, 2020, 02:16 ET BioInvent Interim Report January 1 - June 30, 2020

"BioInvent is fully focused on moving our clinical projects forward. Our successful financing of SEK 625 million has strengthened our institutional...


Aug 21, 2020, 07:04 ET Invitation to presentation of BioInvent's second quarter report 2020 on August 27, 2020

BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2020 on Thursday August 27 at 8.00 a.m. CEST, followed...


Jul 22, 2020, 03:32 ET BioInvent's BI-1206 could improve treatment in several cancers

.Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad...


Jul 13, 2020, 04:10 ET BioInvent to Host Key Opinion Leader Call on Enhancing Checkpoint Inhibitors for the Treatment of Solid Cancers

Call & Webcast on Tuesday, July 21 at 10 a.m. Eastern Time BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) ), a biotech...


Jul 01, 2020, 04:23 ET BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc.

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has further extended the research term under its...


Jun 30, 2020, 07:38 ET BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...